Group 1 - The company has signed a Technology Transfer and Supply Agreement with Fundação Oswaldo Cruz-Bio-Manguinhos (FZ) and BIOMM for the Brazil Production Development Partnership (PDP) project, with a total contract value expected to be no less than RMB 300,000 million (including tax) [1] - The PDP project aims to strengthen the public health system in Brazil and ensure a stable supply of essential medicines by transferring advanced product technology from multinational pharmaceutical companies to local production [1][2] - The company's proposal for the PDP project has been approved by the Brazilian government, establishing it as the only approved plan for the project [2] Group 2 - The contract specifies that the company will transfer the technology for insulin glargine to FZ and supply insulin glargine injection and raw materials to BIOMM, which will in turn transfer the filling technology to FZ [2] - FZ, as the technology recipient and final purchaser, commits to purchasing the agreed quantities and prices from BIOMM over the next 10 years [2]

Core Viewpoint - 甘李药业 has signed significant contracts with Funda o Oswaldo Cruz-Bio-Manguinhos (FZ) and BIOMM S.A. for a partnership project in Brazil, focusing on the production and development of insulin products, which is expected to positively impact the company's future performance [1][2] Group 1 - The company has entered into a Technical Transfer and Supply Agreement with FZ and a Supply Framework Agreement with BIOMM, with the total amount of the latter expected to be no less than 3 billion RMB (including tax) [1] - The PDP project aims to strengthen Brazil's public health system by ensuring a stable supply of essential medicines through local production and technology transfer from multinational pharmaceutical companies [1] - The contracts are part of the company's routine business operations and are not considered related party transactions or major asset restructurings [1] Group 2 - Under the Technical Transfer and Supply Agreement, 甘李药业 will transfer the technology for insulin and supply insulin injection solutions and raw materials to BIOMM, which will in turn supply FZ [2] - The contracts are set to last for 10 years, with the potential to significantly enhance the company's profitability starting from 2025 [2] - In the first half of the year, the company reported a revenue of 2.067 billion RMB, a year-on-year increase of 57.18%, and a net profit of 604 million RMB, up 101.96% year-on-year [2]